Sunitinib in Pancreatic Neuroendocrine Tumors Abstract #708

Introduction: Sunitinib has shown significant improvement of progression-free survival in patients with advanced pancreatic neuroendocrine tumors (pNET).
Aim(s): Assessment of efficacy, safety and tolerability in clinical practice.
Materials and methods: Patients with advanced, differentiated (G1, G2) pNET treated with sunitinib between 2011 and 2012 in Essen and Marburg, Germany, were evaluated in terms of response to therapy, side effects and dose adjustments. All patients had progressive disease when starting sunitinib. Twenty-one patients (six males), median age 64 years (range 28-78) were included in the study.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Harald Lahner
Keywords: sunitinib, pNET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors
Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Anna Kuznetsova
#2795 Molecular Correlation of the Activity of Evofosfamide (EVO) in Combination with Sunitinib (SUN) in Pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial
Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Dr. Enrique Grande
#2685 Apatinib Inhibits Tumor Growth and Angiogenesis in PNET Models
Introduction: Angiogenesis has a pivotal role in the growth and metastasis of pancreatic neuroendocrine tumors (PNETs). Apatinib inhibits angiogenesis as a highly selective KDR inhibitor and has been used to treat advanced gastric cancer and malignancies in clinical settings. However, the efficacy of apatinib in PNETs remains unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Shan Wu
Authors: Wu S, Zhou J, Guo J, Hua Z, ...
#1201 Results of Sunitinib Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Outcome Data from the German NET-Register
Introduction: Among modern treatments (Tx) for neuroendocrine neoplasms (NEN) sunitinib (SUN) has impacted Tx of primarily pancreatic NEN (pNEN).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Sebastian Maasberg
Keywords: sunitinib, outcome
#2948 Efficacy Prediction Using Computed Tomography for Patients with Pancreatic Neuroendocrine Tumors Receiving Sunitinib
Introduction: How to predict the efficacy of sunitinib before treatment initiation was less known.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Wang W, Jin K, ...